FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2190716655> ?p ?o ?g. }

• W2190716655 endingPage "44288" @default.
• W2190716655 startingPage "44274" @default.
• W2190716655 abstract "// Yi Zhang 1, 2, 3, 4, * , Ke Yao 1, 2, 4, * , Chengcheng Shi 1, 3, 4, * , Yanan Jiang 2, * , Kangdong Liu 1, 2, 4 , Song Zhao 3 , Hanyong Chen 1 , Kanamata Reddy 1 , Chengjuan Zhang 1, 2, 5 , Xiaoyu Chang 1 , Joohyun Ryu 1 , Ann M. Bode 1 , Ziming Dong 2 , Zigang Dong 1, 4 1 The Hormel Institute, University of Minnesota, Austin, MN, USA 2 Pathophysiology Department, Basic Medical College, Zhengzhou University, Henan, China 3 The First Affiliated Hospital of Zhengzhou University, Henan, China 4 The China-US (Henan) Hormel Cancer Institute, Henan, China 5 The Affiliated Cancer Hospital of Zhengzhou University, Henan, China * These authors have contributed equally to this work Correspondence to: Zigang Dong, e-mail: zgdong@hi.umn.edu Ziming Dong, e-mail: dongzm@zzu.edu.cn Keywords: gefitinib resistance, non-small cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR) Received: July 20, 2015      Accepted: October 11, 2015      Published: October 26, 2015 ABSTRACT The epidermal growth factor receptor (EGFR) is known to play a critical role in non-small cell lung cancer(NSCLC). Several EGFR tyrosine kinase inhibitors(TKIs), such as gefitinib, have been used as effective clinical therapies for patients with NSCLC. Unfortunately, acquired resistance to gefitinib commonly occurs after 6–12 months of treatment. The resistance is associated with the appearance of the L858R/T790M double mutation of the EGFR. In our present study, we discovered a compound,referred to as 244-MPT, which could suppress either gefitinib-sensitive or -resistant lung cancer cell growth and colony formation, and also suppressed the kinase activity of both wildtype and double mutant (L858R/T790M) EGFR. The underlying mechanism reveals that 244-MPT could interact with either the wildtype or double-mutant EGFR in an ATP-competitive manner and inhibit activity. Treatment with 244-MPT could substantially reduce the phosphorylation of EGFR and its downstream signaling pathways, including Akt and ERK1/2 in gefitinib-sensitive and -resistant cell lines. It was equally effective in suppressing EGFR phosphorylation and downstream signaling in NL20 cells transfected with wildtype, single-mutant (L858R) or mutant (L858R/T790M) EGFR. 244-MPT could also induce apoptosis in a gefitinib-resistant cell line and strongly suppress gefitinib-resistant NSCLC tumor growth in a xenograft mouse model. In addition, 244-MPT could effectively reduce the size of tumors in a gefitinib-resistant NSCLC patient-derived xenograft (PDX) SCID mouse model. Overall, 244-MPT could overcome gefitinib-resistance by directly targeting the EGFR." @default.
• W2190716655 created "2016-06-24" @default.
• W2190716655 creator A5001748432 @default.
• W2190716655 creator A5010041632 @default.
• W2190716655 creator A5035046014 @default.
• W2190716655 creator A5038079761 @default.
• W2190716655 creator A5038431136 @default.
• W2190716655 creator A5044544424 @default.
• W2190716655 creator A5047033898 @default.
• W2190716655 creator A5051769949 @default.
• W2190716655 creator A5056431039 @default.
• W2190716655 creator A5060693660 @default.
• W2190716655 creator A5066596938 @default.
• W2190716655 creator A5067638594 @default.
• W2190716655 creator A5074636897 @default.
• W2190716655 creator A5079308651 @default.
• W2190716655 date "2015-10-26" @default.
• W2190716655 modified "2023-09-23" @default.
• W2190716655 title "244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells" @default.
• W2190716655 cites W1963925139 @default.
• W2190716655 cites W1973219114 @default.
• W2190716655 cites W1974213646 @default.
• W2190716655 cites W1985264867 @default.
• W2190716655 cites W1998971866 @default.
• W2190716655 cites W2001595708 @default.
• W2190716655 cites W2002937040 @default.
• W2190716655 cites W2007528734 @default.
• W2190716655 cites W2017103957 @default.
• W2190716655 cites W2022670843 @default.
• W2190716655 cites W2023512205 @default.
• W2190716655 cites W2023685223 @default.
• W2190716655 cites W2026558596 @default.
• W2190716655 cites W2043696829 @default.
• W2190716655 cites W2053439872 @default.
• W2190716655 cites W2076820499 @default.
• W2190716655 cites W2085286841 @default.
• W2190716655 cites W2088540000 @default.
• W2190716655 cites W2089716357 @default.
• W2190716655 cites W2093613683 @default.
• W2190716655 cites W2110900526 @default.
• W2190716655 cites W2118284186 @default.
• W2190716655 cites W2130479394 @default.
• W2190716655 cites W2135117965 @default.
• W2190716655 cites W2140980839 @default.
• W2190716655 cites W2146041593 @default.
• W2190716655 cites W2159013299 @default.
• W2190716655 cites W2168554018 @default.
• W2190716655 cites W2168554121 @default.
• W2190716655 cites W2170552969 @default.
• W2190716655 cites W2171755671 @default.
• W2190716655 cites W2327362588 @default.
• W2190716655 cites W2917837889 @default.
• W2190716655 doi "https://doi.org/10.18632/oncotarget.6236" @default.
• W2190716655 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4792556" @default.
• W2190716655 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26517520" @default.
• W2190716655 hasPublicationYear "2015" @default.
• W2190716655 type Work @default.
• W2190716655 sameAs 2190716655 @default.
• W2190716655 citedByCount "14" @default.
• W2190716655 countsByYear W21907166552016 @default.
• W2190716655 countsByYear W21907166552017 @default.
• W2190716655 countsByYear W21907166552018 @default.
• W2190716655 countsByYear W21907166552020 @default.
• W2190716655 countsByYear W21907166552021 @default.
• W2190716655 countsByYear W21907166552023 @default.
• W2190716655 crossrefType "journal-article" @default.
• W2190716655 hasAuthorship W2190716655A5001748432 @default.
• W2190716655 hasAuthorship W2190716655A5010041632 @default.
• W2190716655 hasAuthorship W2190716655A5035046014 @default.
• W2190716655 hasAuthorship W2190716655A5038079761 @default.
• W2190716655 hasAuthorship W2190716655A5038431136 @default.
• W2190716655 hasAuthorship W2190716655A5044544424 @default.
• W2190716655 hasAuthorship W2190716655A5047033898 @default.
• W2190716655 hasAuthorship W2190716655A5051769949 @default.
• W2190716655 hasAuthorship W2190716655A5056431039 @default.
• W2190716655 hasAuthorship W2190716655A5060693660 @default.
• W2190716655 hasAuthorship W2190716655A5066596938 @default.
• W2190716655 hasAuthorship W2190716655A5067638594 @default.
• W2190716655 hasAuthorship W2190716655A5074636897 @default.
• W2190716655 hasAuthorship W2190716655A5079308651 @default.
• W2190716655 hasBestOaLocation W21907166551 @default.
• W2190716655 hasConcept C121608353 @default.
• W2190716655 hasConcept C126322002 @default.
• W2190716655 hasConcept C143998085 @default.
• W2190716655 hasConcept C2776256026 @default.
• W2190716655 hasConcept C2777930144 @default.
• W2190716655 hasConcept C2779438470 @default.
• W2190716655 hasConcept C2780580887 @default.
• W2190716655 hasConcept C502942594 @default.
• W2190716655 hasConcept C71924100 @default.
• W2190716655 hasConceptScore W2190716655C121608353 @default.
• W2190716655 hasConceptScore W2190716655C126322002 @default.
• W2190716655 hasConceptScore W2190716655C143998085 @default.
• W2190716655 hasConceptScore W2190716655C2776256026 @default.
• W2190716655 hasConceptScore W2190716655C2777930144 @default.
• W2190716655 hasConceptScore W2190716655C2779438470 @default.
• W2190716655 hasConceptScore W2190716655C2780580887 @default.
• W2190716655 hasConceptScore W2190716655C502942594 @default.

• next